Evaluate Bioequivalence of Voriconazole(200mg/Vial) .

Inclusion criteria

• Healthy adult male or female subjects between 20-45 years of age (inclusive) at the screening visit.
• Body weight within 80-120% of ideal body weight but not less than 45kg at the screening visit.

• Ideal body weight (kg) = [height (cm) - 80] ´ 0.7 for male subjects
• Ideal body weight (kg) = [height (cm) - 70] ´ 0.6 for female subjects
• Acceptable medical history and physical examination including:

• no particular clinically significant abnormalities in Electrocardiogram(ECG) results within six months prior to Period I dosing.
• no particular clinical significance in general disease history within two months prior to Period I dosing.
• Acceptable biochemistry determinations (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to Period I dosing, which includes ASpartate aminoTransferase (AST), ALanine aminoTransferase (ALT), Gamma-Glutamyl-Transpeptidase (g-GT), alkaline phosphatase, total bilirubin, albumin, glucose, BUN, uric acid, creatinine, total cholesterol, and triglyceride (TG).
• Acceptable hematology (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to Period I dosing, which includes hemoglobin, hematocrit, red blood cell count, white blood cell count with differentials and platelets.
• Acceptable urinalysis (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to Period I dosing, which includes pH, blood, glucose, ketones, bilirubin and protein.
• Female of childbearing potential practicing an acceptable method of birth control for the duration of the study.
• Have signed the written informed consent to participate in this study.

Exclusion criteria

• A clinically significant disorder involving the cardiovascular, respiratory, hepatic, renal, gastrointestinal, immunologic, hematologic, endocrine or neurologic system(s) or psychiatric disease (as determined by the investigator).
• A clinically significant illness or surgery within four weeks prior to Period I dosing (as determined by the investigator).
• History of gastrointestinal obstruction, inflammatory bowel disease, gallbladder disease, pancreas disorder over last two years or history of gastrointestinal tract surgery over last five years.
• History of kidney disease or urination problem over last two years deemed by the investigator to be clinically significant.
• Known or suspected history of drug abuse within lifetime as judged by the investigator.
• History of alcohol addiction or abuse within last five years as judged by the investigator.
• History of allergic response(s) to voriconazole, any other drugs analogous to voriconazole, or any antibiotics.
• Evidence of chronic or acute infectious diseases.